The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

Not unlike Regeneron's acquisition of 23andMe, Predictive Oncology's AI-driven breakthroughs reflect a broader transformation ...

Stocks from pharmaceutical companies and healthcare spaces dominated analysts' choices for Thursday's trading session.

GSK (GSK) stock gains as FDA broadens the label for the company's asthma therapy Nucala l for COPD with an eosinophilic ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

With antibiotic-resistant gonorrhea on the rise, the vaccine could provide a way to prevent the disease from spreading.

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.